If you have non-cystic fibrosis bronchiectasis, you’re likely an expert on the “lung side” of the disease — the stubborn mucus, the nagging cough, and the constant threat of a flare-up. But by causing ...

Bronchiectasis is a chronic lung condition in which your airways, or bronchi, widen permanently and become scarred. It may cause a persistent cough, large daily production of mucus (sputum or phlegm), ...

DPP‑1 inhibitors and long‑term macrolides appeared to effectively reduce the frequency of exacerbations in patients with non-cystic fibrosis bronchiectasis compared with placebo, with macrolides ...

Please provide your email address to receive an email when new articles are posted on . Diagnosis-related anxiety, depression or fear was reported by a larger proportion of women vs. men. After being ...

It started out as a typical hot yoga class for Lavonda. The North Carolina resident was used to strenuous workouts, but on this day in 2008 she felt faint as she went through the sequence of poses.

Miami (October 23, 2025) – The Bronchiectasis and NTM Association announced today that two abstracts using Bronchiectasis and NTM Research Registry data were presented at CHEST 2025, held October ...

Queen's University Belfast-led research reports on a multicenter trial finding no significant reduction in pulmonary exacerbations with hypertonic saline or carbocisteine over 52 weeks among adults ...

Bronchiectasis guidelines are inconsistent with regard to the effectiveness of mucoactive agents, and their use varies geographically. Large trials are needed to assess safety and effectiveness. For ...

Mucoactive agents did little to stave off pulmonary exacerbations of non-cystic fibrosis bronchiectasis, the CLEAR trial showed. In the two-by-two factorial trial testing hypertonic saline and ...

Add Yahoo as a preferred source to see more of our stories on Google. Sep. 24—(StatePoint) Getting the correct treatment for bronchiectasis, a chronic lung condition affecting 350,000 to 500,000 ...